Minimum criteria for defining induced mesenchymal stem cells

• Published in: Cell biology international Vol. 46; no. 6; pp. 986 - 989
• Main Authors: Choudhery, Mahmood S., Mahmood, Ruhma, Harris, David T., Ahmad, Fridoon J.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.06.2022
• Subjects: additional characterization; CD105 antigen; CD11b antigen; CD14 antigen; CD19 antigen; CD29 antigen; CD34 antigen; CD44 antigen; CD45 antigen; CD73 antigen; Cell number; clinical applications; iMSCs; iPSCs; Mesenchymal stem cells; minimum criteria; Paracrine signalling; Pluripotency; primary MSCs; Stem cells; Teratoma; primary MSCs; iPSCs; minimum criteria; iMSCs; clinical applications; additional characterization
• ISSN: 1065-6995; 1095-8355
• DOI: 10.1002/cbin.11790

Mesenchymal stem cells (MSCs) are a promising cell type for cell‐based therapies. The therapeutic potential of MSCs has been verified in preclinical and clinical studies, however; low cell number in adult tissues, restricted expansion and differentiation capacity, and donor‐related heterogeneity limit their use. To address these issues, there has been considerable interest in induced pluripotent stem cells (iPSCs) derived MSCs (induced mesenchymal stem cells [iMSCs]). Investigators obtain iMSCs from iPSCs of different origins, with variable methods of generation and expansion. Results of current studies have suggested iMSCs as a unique alternative source of MSCs. However, iMSCs are defined using the same criteria (proposed previously for primary MSCs by the International Society for Cellular Therapy [ISCT]) without realizing the distinct nature of iMSCs as compared to primary MSCs. To rationally define iMSCs, additional characterization is proposed along with ISCT's minimum criteria for defining primary MSCs. Minimum criteria for defining iMSCs should include (1) spindle‐shaped morphology, (2) plastic adherent growth, (3) positive expression of CD29, CD44, CD73, CD90, CD105, along with negative expression of hematopoietic markers (CD45, CD34, CD14 or CD11b, CD79α or CD19, HLA‐DR), (4) lack of expression of iPSCs induction factors, (5) trilineage differentiation potential, (6) lack of ability to form teratoma, and (7) release of MSC relevant paracrine factors. Defining the minimum criteria for iMSCs will be of great interest in the field and will provide a uniform description and identification of iMSCs to expedite progress in the field. Furthermore, due to increased interest in the clinical use of iMSCs, the above‐mentioned additional characterization before the clinical application is important to avoid unwanted complications for recipients.